Cardiovascular Systems, Inc. Reports the First Patient Enrollment of Diamondback 360 Peripheral Orbital Atherectomy System in Japan
Shots:
- The company has initiated the study (KAIZEN) evaluating the safety and efficacy of CSI’s Diamondback 360© Peripheral OAS, a minimally invasive, single-use, the catheter-based device in 100 patients with calcified plaque associated with peripheral artery disease (PAD) at ~12 study sites. The study was led by Hiroyoshi Yokoi
- OAS showed safety and efficacy in the US population. Diamondback 360 Coronary OAS reduces sev. calcium enabling effective stent delivery and helping to improve the results of percutaneous coronary intervention (PCI) and stent expansion
- To restore blood flow, the OAS orbiting crown reduces and modifies calcified plaque while protecting the healthy vessel wall
Ref: Businesswire | Image: Cardiovascular Systems
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
